Company Overview - Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotech company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers [1] - The company is pioneering innovative RNAi therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers [4] - Silexion's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer [4] - The company is advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies [4] Upcoming Presentation - Silexion will present a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, California, from January 23-25, 2025 [1] - The presentation will focus on SIL-204 siRNA, both free and encapsulated in extended release microparticles, for the treatment of localized and systemic cancer with specific KRAS mutations (G12x, Q61H, or G13D) [4] - The abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 [3] - The poster will be available on Silexion Therapeutics' website under the "Our Science" section following the presentation [3] Presentation Details - Title: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation [4] - Presenter: Mitchell Shirvan, Ph.D. [4] - Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract [4] - Abstract Number: 745 [4] - Session Date & Time: January 24, 2025, 11:30 AM-1:00 PM PST [4] Industry Context - The 2025 ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and provide oncologists with the information needed to deliver high-quality patient care [2]
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium